P
Proteon Pharmaceuticals
Uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics
About Proteon Pharmaceuticals
Proteon Pharmaceuticals leverages precision biology to develop microbiome protection solutions aimed at improving animal and human health. Operating in the animal health sector, the company partners with farmers to enhance the economic efficiency of farms through environmentally sustainable and natural solutions. Proteon's core products include feed additives that prevent and eliminate infections in poultry and aquaculture, thereby reducing the need for antibiotics. The company employs advanced technologies such as bioinformatics, Artificial Intelligence, genomic sequencing, materials engineering, and molecular biology in its proprietary Phage Development Platform. This platform has been refined over more than a decade of research and development in bacteriophages, which are viruses that target and destroy specific bacteria. By focusing on precision-targeted solutions, Proteon aims to address the overuse of antibiotics in livestock farming, which is a significant concern for both animal and human health. The business model involves partnering with farmers and distributors to deliver these innovative solutions, generating revenue through product sales and strategic partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Łódź, Poland
- Employees
- 49
- Open positions
- None listed
- Dealroom signal
- 59.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, AgriTech
- Sector
- Biotech & Life Sciences, Aquaculture, Biotechnology, Poultry, Sustainable Development Goals, Dairy Farming, Biotech and Pharma, Climate Tech, Blue Economy, Blue Biotechnology
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Proteon Pharmaceuticals is 470 monthly website visits, down 66.4% over the last three months. Proteon Pharmaceuticals's team declined 32.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Aqua-Spark
Montis Capital
Polish Development Fund - PFR
Seventure Partners
Nutreco
Other known investors3 additional known investors
1000 Ocean Startups
KU Innovation Park
Newtree Impact
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Proteon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proteon Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







